nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—CYP3A4—breast cancer	0.106	1	CbGaD
Disopyramide—Doxylamine—Toremifene—breast cancer	0.0692	0.147	CrCrCtD
Disopyramide—Dextropropoxyphene—Toremifene—breast cancer	0.0657	0.139	CrCrCtD
Disopyramide—Levomethadyl Acetate—Tamoxifen—breast cancer	0.0503	0.107	CrCrCtD
Disopyramide—Methadyl Acetate—Tamoxifen—breast cancer	0.0503	0.107	CrCrCtD
Disopyramide—Clofedanol—Toremifene—breast cancer	0.0475	0.101	CrCrCtD
Disopyramide—Doxylamine—Tamoxifen—breast cancer	0.0434	0.0922	CrCrCtD
Disopyramide—Dextropropoxyphene—Tamoxifen—breast cancer	0.0412	0.0875	CrCrCtD
Disopyramide—Tripelennamine—Tamoxifen—breast cancer	0.0393	0.0834	CrCrCtD
Disopyramide—Methadone—Tamoxifen—breast cancer	0.0345	0.0732	CrCrCtD
Disopyramide—Clofedanol—Tamoxifen—breast cancer	0.0298	0.0633	CrCrCtD
Disopyramide—SLC22A2—Vinblastine—breast cancer	0.026	0.126	CbGbCtD
Disopyramide—CYP3A4—Exemestane—breast cancer	0.024	0.116	CbGbCtD
Disopyramide—CYP3A4—Letrozole—breast cancer	0.0204	0.0987	CbGbCtD
Disopyramide—CYP3A4—Anastrozole—breast cancer	0.0182	0.088	CbGbCtD
Disopyramide—CYP3A4—Toremifene—breast cancer	0.0166	0.0805	CbGbCtD
Disopyramide—CYP3A4—Fulvestrant—breast cancer	0.0154	0.0748	CbGbCtD
Disopyramide—CYP3A4—Thiotepa—breast cancer	0.0138	0.0667	CbGbCtD
Disopyramide—CYP3A4—Ixabepilone—breast cancer	0.0126	0.061	CbGbCtD
Disopyramide—CYP3A4—Lapatinib—breast cancer	0.0121	0.0587	CbGbCtD
Disopyramide—CYP3A4—Raloxifene—breast cancer	0.00918	0.0445	CbGbCtD
Disopyramide—CYP3A4—Vinorelbine—breast cancer	0.00672	0.0326	CbGbCtD
Disopyramide—CYP3A4—Tamoxifen—breast cancer	0.00607	0.0294	CbGbCtD
Disopyramide—CYP3A4—Mitoxantrone—breast cancer	0.00592	0.0287	CbGbCtD
Disopyramide—CYP3A4—Paclitaxel—breast cancer	0.00472	0.0229	CbGbCtD
Disopyramide—CYP3A4—Irinotecan—breast cancer	0.00466	0.0226	CbGbCtD
Disopyramide—CYP3A4—Vinblastine—breast cancer	0.00414	0.0201	CbGbCtD
Disopyramide—CYP3A4—Docetaxel—breast cancer	0.00341	0.0165	CbGbCtD
Disopyramide—CHRM3—muscle of abdomen—breast cancer	0.00279	0.25	CbGeAlD
Disopyramide—CYP3A4—Doxorubicin—breast cancer	0.00255	0.0123	CbGbCtD
Disopyramide—KCND2—pituitary gland—breast cancer	0.000742	0.0666	CbGeAlD
Disopyramide—KCND2—adipose tissue—breast cancer	0.000738	0.0664	CbGeAlD
Disopyramide—KCND3—uterus—breast cancer	0.000658	0.0591	CbGeAlD
Disopyramide—KCND3—adipose tissue—breast cancer	0.000644	0.0578	CbGeAlD
Disopyramide—KCND2—female gonad—breast cancer	0.000618	0.0555	CbGeAlD
Disopyramide—KCND3—adrenal gland—breast cancer	0.000578	0.0519	CbGeAlD
Disopyramide—ORM1—endometrium—breast cancer	0.000392	0.0352	CbGeAlD
Disopyramide—KCND3—lymph node—breast cancer	0.000346	0.0311	CbGeAlD
Disopyramide—ORM1—female reproductive system—breast cancer	0.000324	0.0291	CbGeAlD
Disopyramide—SLC22A1—adipose tissue—breast cancer	0.000323	0.029	CbGeAlD
Disopyramide—ORM1—bone marrow—breast cancer	0.000306	0.0275	CbGeAlD
Disopyramide—Fesoterodine—CYP2D6—breast cancer	0.000296	0.155	CrCbGaD
Disopyramide—CHRM1—female reproductive system—breast cancer	0.000275	0.0247	CbGeAlD
Disopyramide—ORM1—endocrine gland—breast cancer	0.000274	0.0247	CbGeAlD
Disopyramide—CHRM3—adipose tissue—breast cancer	0.000268	0.0241	CbGeAlD
Disopyramide—CHRM2—endocrine gland—breast cancer	0.000256	0.023	CbGeAlD
Disopyramide—Fesoterodine—CYP3A4—breast cancer	0.000254	0.133	CrCbGaD
Disopyramide—SLC22A1—endocrine gland—breast cancer	0.000251	0.0226	CbGeAlD
Disopyramide—CHRM3—female reproductive system—breast cancer	0.000246	0.0221	CbGeAlD
Disopyramide—CHRM1—endocrine gland—breast cancer	0.000233	0.0209	CbGeAlD
Disopyramide—CHRM3—female gonad—breast cancer	0.000224	0.0201	CbGeAlD
Disopyramide—Fesoterodine—ABCB1—breast cancer	0.000212	0.11	CrCbGaD
Disopyramide—CHRM3—endocrine gland—breast cancer	0.000208	0.0187	CbGeAlD
Disopyramide—Levomethadyl Acetate—CYP19A1—breast cancer	0.000197	0.103	CrCbGaD
Disopyramide—ORM1—lymph node—breast cancer	0.00019	0.017	CbGeAlD
Disopyramide—Tripelennamine—CYP2D6—breast cancer	0.000166	0.0867	CrCbGaD
Disopyramide—CYP3A4—female reproductive system—breast cancer	0.000135	0.0122	CbGeAlD
Disopyramide—Tolterodine—CYP2D6—breast cancer	0.000132	0.0691	CrCbGaD
Disopyramide—Methadone—CYP19A1—breast cancer	0.000116	0.0603	CrCbGaD
Disopyramide—CYP3A4—endocrine gland—breast cancer	0.000115	0.0103	CbGeAlD
Disopyramide—Tolterodine—CYP3A4—breast cancer	0.000114	0.0593	CrCbGaD
Disopyramide—Dextropropoxyphene—CYP2D6—breast cancer	9.32e-05	0.0487	CrCbGaD
Disopyramide—Levomethadyl Acetate—CYP3A4—breast cancer	9.25e-05	0.0483	CrCbGaD
Disopyramide—Dextropropoxyphene—CYP3A4—breast cancer	8e-05	0.0418	CrCbGaD
Disopyramide—Rash—Thiotepa—breast cancer	6.37e-05	0.000467	CcSEcCtD
Disopyramide—Dermatitis—Thiotepa—breast cancer	6.36e-05	0.000466	CcSEcCtD
Disopyramide—Agranulocytosis—Methotrexate—breast cancer	6.36e-05	0.000466	CcSEcCtD
Disopyramide—Dyspnoea—Paclitaxel—breast cancer	6.34e-05	0.000465	CcSEcCtD
Disopyramide—Headache—Thiotepa—breast cancer	6.33e-05	0.000464	CcSEcCtD
Disopyramide—Somnolence—Paclitaxel—breast cancer	6.33e-05	0.000464	CcSEcCtD
Disopyramide—Methadone—CYP2D6—breast cancer	6.33e-05	0.033	CrCbGaD
Disopyramide—Chest pain—Docetaxel—breast cancer	6.29e-05	0.000461	CcSEcCtD
Disopyramide—Loss of consciousness—Capecitabine—breast cancer	6.29e-05	0.000461	CcSEcCtD
Disopyramide—Nausea—Vinorelbine—breast cancer	6.28e-05	0.00046	CcSEcCtD
Disopyramide—Dyspepsia—Paclitaxel—breast cancer	6.26e-05	0.000459	CcSEcCtD
Disopyramide—Asthenia—Irinotecan—breast cancer	6.26e-05	0.000459	CcSEcCtD
Disopyramide—Asthenia—Mitoxantrone—breast cancer	6.26e-05	0.000459	CcSEcCtD
Disopyramide—Dysuria—Doxorubicin—breast cancer	6.19e-05	0.000454	CcSEcCtD
Disopyramide—Neutropenia—Doxorubicin—breast cancer	6.19e-05	0.000454	CcSEcCtD
Disopyramide—Decreased appetite—Paclitaxel—breast cancer	6.19e-05	0.000453	CcSEcCtD
Disopyramide—Dry mouth—Docetaxel—breast cancer	6.15e-05	0.000451	CcSEcCtD
Disopyramide—Fatigue—Paclitaxel—breast cancer	6.13e-05	0.00045	CcSEcCtD
Disopyramide—Hepatitis—Methotrexate—breast cancer	6.12e-05	0.000448	CcSEcCtD
Disopyramide—Pollakiuria—Doxorubicin—breast cancer	6.11e-05	0.000448	CcSEcCtD
Disopyramide—Asthenia—Gemcitabine—breast cancer	6.1e-05	0.000447	CcSEcCtD
Disopyramide—Chest pain—Capecitabine—breast cancer	6.09e-05	0.000446	CcSEcCtD
Disopyramide—Constipation—Paclitaxel—breast cancer	6.08e-05	0.000446	CcSEcCtD
Disopyramide—Pain—Paclitaxel—breast cancer	6.08e-05	0.000446	CcSEcCtD
Disopyramide—Confusional state—Docetaxel—breast cancer	6.08e-05	0.000446	CcSEcCtD
Disopyramide—Oedema—Docetaxel—breast cancer	6.03e-05	0.000442	CcSEcCtD
Disopyramide—Weight increased—Doxorubicin—breast cancer	6.02e-05	0.000441	CcSEcCtD
Disopyramide—Discomfort—Capecitabine—breast cancer	6.02e-05	0.000441	CcSEcCtD
Disopyramide—Pruritus—Gemcitabine—breast cancer	6.01e-05	0.000441	CcSEcCtD
Disopyramide—Nausea—Thiotepa—breast cancer	6e-05	0.00044	CcSEcCtD
Disopyramide—Diarrhoea—Mitoxantrone—breast cancer	5.97e-05	0.000437	CcSEcCtD
Disopyramide—Diarrhoea—Irinotecan—breast cancer	5.97e-05	0.000437	CcSEcCtD
Disopyramide—Dry mouth—Capecitabine—breast cancer	5.96e-05	0.000437	CcSEcCtD
Disopyramide—Agranulocytosis—Epirubicin—breast cancer	5.95e-05	0.000436	CcSEcCtD
Disopyramide—Shock—Docetaxel—breast cancer	5.93e-05	0.000435	CcSEcCtD
Disopyramide—Pruritus—Fluorouracil—breast cancer	5.91e-05	0.000433	CcSEcCtD
Disopyramide—Thrombocytopenia—Docetaxel—breast cancer	5.91e-05	0.000433	CcSEcCtD
Disopyramide—Drowsiness—Doxorubicin—breast cancer	5.9e-05	0.000432	CcSEcCtD
Disopyramide—Confusional state—Capecitabine—breast cancer	5.89e-05	0.000431	CcSEcCtD
Disopyramide—Feeling abnormal—Paclitaxel—breast cancer	5.86e-05	0.00043	CcSEcCtD
Disopyramide—Skin disorder—Docetaxel—breast cancer	5.86e-05	0.000429	CcSEcCtD
Disopyramide—Oedema—Capecitabine—breast cancer	5.84e-05	0.000428	CcSEcCtD
Disopyramide—Bradycardia—Epirubicin—breast cancer	5.83e-05	0.000427	CcSEcCtD
Disopyramide—Diarrhoea—Gemcitabine—breast cancer	5.81e-05	0.000426	CcSEcCtD
Disopyramide—Dizziness—Irinotecan—breast cancer	5.77e-05	0.000423	CcSEcCtD
Disopyramide—Anorexia—Docetaxel—breast cancer	5.75e-05	0.000421	CcSEcCtD
Disopyramide—Shock—Capecitabine—breast cancer	5.75e-05	0.000421	CcSEcCtD
Disopyramide—Hepatitis—Epirubicin—breast cancer	5.73e-05	0.00042	CcSEcCtD
Disopyramide—Diarrhoea—Fluorouracil—breast cancer	5.72e-05	0.000419	CcSEcCtD
Disopyramide—Thrombocytopenia—Capecitabine—breast cancer	5.72e-05	0.000419	CcSEcCtD
Disopyramide—Hypoaesthesia—Epirubicin—breast cancer	5.7e-05	0.000417	CcSEcCtD
Disopyramide—Skin disorder—Capecitabine—breast cancer	5.67e-05	0.000416	CcSEcCtD
Disopyramide—Urticaria—Paclitaxel—breast cancer	5.65e-05	0.000414	CcSEcCtD
Disopyramide—Hyperhidrosis—Capecitabine—breast cancer	5.65e-05	0.000414	CcSEcCtD
Disopyramide—Hypotension—Docetaxel—breast cancer	5.64e-05	0.000413	CcSEcCtD
Disopyramide—Body temperature increased—Paclitaxel—breast cancer	5.63e-05	0.000412	CcSEcCtD
Disopyramide—Anorexia—Capecitabine—breast cancer	5.57e-05	0.000408	CcSEcCtD
Disopyramide—Vomiting—Mitoxantrone—breast cancer	5.55e-05	0.000407	CcSEcCtD
Disopyramide—Vomiting—Irinotecan—breast cancer	5.55e-05	0.000407	CcSEcCtD
Disopyramide—Dizziness—Fluorouracil—breast cancer	5.53e-05	0.000405	CcSEcCtD
Disopyramide—Agranulocytosis—Doxorubicin—breast cancer	5.51e-05	0.000404	CcSEcCtD
Disopyramide—Rash—Irinotecan—breast cancer	5.5e-05	0.000403	CcSEcCtD
Disopyramide—Rash—Mitoxantrone—breast cancer	5.5e-05	0.000403	CcSEcCtD
Disopyramide—Dermatitis—Mitoxantrone—breast cancer	5.5e-05	0.000403	CcSEcCtD
Disopyramide—Dermatitis—Irinotecan—breast cancer	5.5e-05	0.000403	CcSEcCtD
Disopyramide—Headache—Irinotecan—breast cancer	5.47e-05	0.000401	CcSEcCtD
Disopyramide—Headache—Mitoxantrone—breast cancer	5.47e-05	0.000401	CcSEcCtD
Disopyramide—Hypotension—Capecitabine—breast cancer	5.46e-05	0.0004	CcSEcCtD
Disopyramide—Insomnia—Docetaxel—breast cancer	5.45e-05	0.0004	CcSEcCtD
Disopyramide—Methadone—CYP3A4—breast cancer	5.43e-05	0.0283	CrCbGaD
Disopyramide—Paraesthesia—Docetaxel—breast cancer	5.42e-05	0.000397	CcSEcCtD
Disopyramide—Vomiting—Gemcitabine—breast cancer	5.4e-05	0.000396	CcSEcCtD
Disopyramide—Bradycardia—Doxorubicin—breast cancer	5.39e-05	0.000395	CcSEcCtD
Disopyramide—Dyspnoea—Docetaxel—breast cancer	5.38e-05	0.000394	CcSEcCtD
Disopyramide—Somnolence—Docetaxel—breast cancer	5.36e-05	0.000393	CcSEcCtD
Disopyramide—Rash—Gemcitabine—breast cancer	5.36e-05	0.000393	CcSEcCtD
Disopyramide—Dermatitis—Gemcitabine—breast cancer	5.35e-05	0.000392	CcSEcCtD
Disopyramide—Headache—Gemcitabine—breast cancer	5.32e-05	0.00039	CcSEcCtD
Disopyramide—Vomiting—Fluorouracil—breast cancer	5.31e-05	0.000389	CcSEcCtD
Disopyramide—Dyspepsia—Docetaxel—breast cancer	5.31e-05	0.000389	CcSEcCtD
Disopyramide—Hepatitis—Doxorubicin—breast cancer	5.3e-05	0.000388	CcSEcCtD
Disopyramide—Insomnia—Capecitabine—breast cancer	5.28e-05	0.000387	CcSEcCtD
Disopyramide—Hypoaesthesia—Doxorubicin—breast cancer	5.27e-05	0.000386	CcSEcCtD
Disopyramide—Rash—Fluorouracil—breast cancer	5.27e-05	0.000386	CcSEcCtD
Disopyramide—Dermatitis—Fluorouracil—breast cancer	5.26e-05	0.000386	CcSEcCtD
Disopyramide—Paraesthesia—Capecitabine—breast cancer	5.24e-05	0.000384	CcSEcCtD
Disopyramide—Decreased appetite—Docetaxel—breast cancer	5.24e-05	0.000384	CcSEcCtD
Disopyramide—Headache—Fluorouracil—breast cancer	5.23e-05	0.000384	CcSEcCtD
Disopyramide—Dysgeusia—Methotrexate—breast cancer	5.22e-05	0.000382	CcSEcCtD
Disopyramide—Dyspnoea—Capecitabine—breast cancer	5.21e-05	0.000382	CcSEcCtD
Disopyramide—Fatigue—Docetaxel—breast cancer	5.2e-05	0.000381	CcSEcCtD
Disopyramide—Nausea—Mitoxantrone—breast cancer	5.18e-05	0.00038	CcSEcCtD
Disopyramide—Nausea—Irinotecan—breast cancer	5.18e-05	0.00038	CcSEcCtD
Disopyramide—Constipation—Docetaxel—breast cancer	5.16e-05	0.000378	CcSEcCtD
Disopyramide—Pain—Docetaxel—breast cancer	5.16e-05	0.000378	CcSEcCtD
Disopyramide—Dyspepsia—Capecitabine—breast cancer	5.14e-05	0.000377	CcSEcCtD
Disopyramide—Arrhythmia—Epirubicin—breast cancer	5.12e-05	0.000375	CcSEcCtD
Disopyramide—Asthenia—Paclitaxel—breast cancer	5.11e-05	0.000374	CcSEcCtD
Disopyramide—Decreased appetite—Capecitabine—breast cancer	5.08e-05	0.000372	CcSEcCtD
Disopyramide—Nausea—Gemcitabine—breast cancer	5.05e-05	0.00037	CcSEcCtD
Disopyramide—Fatigue—Capecitabine—breast cancer	5.03e-05	0.000369	CcSEcCtD
Disopyramide—Pruritus—Paclitaxel—breast cancer	5.03e-05	0.000369	CcSEcCtD
Disopyramide—Vision blurred—Methotrexate—breast cancer	5.02e-05	0.000368	CcSEcCtD
Disopyramide—Constipation—Capecitabine—breast cancer	4.99e-05	0.000366	CcSEcCtD
Disopyramide—Pain—Capecitabine—breast cancer	4.99e-05	0.000366	CcSEcCtD
Disopyramide—Feeling abnormal—Docetaxel—breast cancer	4.97e-05	0.000364	CcSEcCtD
Disopyramide—Nausea—Fluorouracil—breast cancer	4.96e-05	0.000364	CcSEcCtD
Disopyramide—Ill-defined disorder—Methotrexate—breast cancer	4.94e-05	0.000362	CcSEcCtD
Disopyramide—Flatulence—Epirubicin—breast cancer	4.91e-05	0.00036	CcSEcCtD
Disopyramide—Tension—Epirubicin—breast cancer	4.89e-05	0.000358	CcSEcCtD
Disopyramide—Dysgeusia—Epirubicin—breast cancer	4.88e-05	0.000358	CcSEcCtD
Disopyramide—Diarrhoea—Paclitaxel—breast cancer	4.87e-05	0.000357	CcSEcCtD
Disopyramide—Nervousness—Epirubicin—breast cancer	4.84e-05	0.000355	CcSEcCtD
Disopyramide—Feeling abnormal—Capecitabine—breast cancer	4.81e-05	0.000353	CcSEcCtD
Disopyramide—Malaise—Methotrexate—breast cancer	4.8e-05	0.000352	CcSEcCtD
Disopyramide—Vertigo—Methotrexate—breast cancer	4.79e-05	0.000351	CcSEcCtD
Disopyramide—Body temperature increased—Docetaxel—breast cancer	4.77e-05	0.000349	CcSEcCtD
Disopyramide—Arrhythmia—Doxorubicin—breast cancer	4.73e-05	0.000347	CcSEcCtD
Disopyramide—Dizziness—Paclitaxel—breast cancer	4.71e-05	0.000345	CcSEcCtD
Disopyramide—Vision blurred—Epirubicin—breast cancer	4.7e-05	0.000344	CcSEcCtD
Disopyramide—Urticaria—Capecitabine—breast cancer	4.64e-05	0.00034	CcSEcCtD
Disopyramide—Ill-defined disorder—Epirubicin—breast cancer	4.62e-05	0.000339	CcSEcCtD
Disopyramide—Body temperature increased—Capecitabine—breast cancer	4.62e-05	0.000338	CcSEcCtD
Disopyramide—Flatulence—Doxorubicin—breast cancer	4.54e-05	0.000333	CcSEcCtD
Disopyramide—Chest pain—Methotrexate—breast cancer	4.53e-05	0.000332	CcSEcCtD
Disopyramide—Tension—Doxorubicin—breast cancer	4.53e-05	0.000332	CcSEcCtD
Disopyramide—Vomiting—Paclitaxel—breast cancer	4.52e-05	0.000332	CcSEcCtD
Disopyramide—Methadone—ABCB1—breast cancer	4.52e-05	0.0236	CrCbGaD
Disopyramide—Dysgeusia—Doxorubicin—breast cancer	4.52e-05	0.000331	CcSEcCtD
Disopyramide—Malaise—Epirubicin—breast cancer	4.49e-05	0.000329	CcSEcCtD
Disopyramide—Rash—Paclitaxel—breast cancer	4.49e-05	0.000329	CcSEcCtD
Disopyramide—Dermatitis—Paclitaxel—breast cancer	4.48e-05	0.000328	CcSEcCtD
Disopyramide—Discomfort—Methotrexate—breast cancer	4.48e-05	0.000328	CcSEcCtD
Disopyramide—Nervousness—Doxorubicin—breast cancer	4.48e-05	0.000328	CcSEcCtD
Disopyramide—Vertigo—Epirubicin—breast cancer	4.48e-05	0.000328	CcSEcCtD
Disopyramide—Syncope—Epirubicin—breast cancer	4.47e-05	0.000328	CcSEcCtD
Disopyramide—Headache—Paclitaxel—breast cancer	4.46e-05	0.000327	CcSEcCtD
Disopyramide—Confusional state—Methotrexate—breast cancer	4.38e-05	0.000321	CcSEcCtD
Disopyramide—Loss of consciousness—Epirubicin—breast cancer	4.38e-05	0.000321	CcSEcCtD
Disopyramide—Vision blurred—Doxorubicin—breast cancer	4.35e-05	0.000319	CcSEcCtD
Disopyramide—Asthenia—Docetaxel—breast cancer	4.33e-05	0.000317	CcSEcCtD
Disopyramide—Ill-defined disorder—Doxorubicin—breast cancer	4.28e-05	0.000314	CcSEcCtD
Disopyramide—Pruritus—Docetaxel—breast cancer	4.27e-05	0.000313	CcSEcCtD
Disopyramide—Thrombocytopenia—Methotrexate—breast cancer	4.26e-05	0.000312	CcSEcCtD
Disopyramide—Chest pain—Epirubicin—breast cancer	4.24e-05	0.000311	CcSEcCtD
Disopyramide—Nausea—Paclitaxel—breast cancer	4.23e-05	0.00031	CcSEcCtD
Disopyramide—Skin disorder—Methotrexate—breast cancer	4.22e-05	0.000309	CcSEcCtD
Disopyramide—Hyperhidrosis—Methotrexate—breast cancer	4.2e-05	0.000308	CcSEcCtD
Disopyramide—Discomfort—Epirubicin—breast cancer	4.19e-05	0.000307	CcSEcCtD
Disopyramide—Asthenia—Capecitabine—breast cancer	4.19e-05	0.000307	CcSEcCtD
Disopyramide—Malaise—Doxorubicin—breast cancer	4.16e-05	0.000305	CcSEcCtD
Disopyramide—Dry mouth—Epirubicin—breast cancer	4.15e-05	0.000304	CcSEcCtD
Disopyramide—Vertigo—Doxorubicin—breast cancer	4.14e-05	0.000304	CcSEcCtD
Disopyramide—Anorexia—Methotrexate—breast cancer	4.14e-05	0.000304	CcSEcCtD
Disopyramide—Syncope—Doxorubicin—breast cancer	4.14e-05	0.000303	CcSEcCtD
Disopyramide—Pruritus—Capecitabine—breast cancer	4.13e-05	0.000303	CcSEcCtD
Disopyramide—Diarrhoea—Docetaxel—breast cancer	4.13e-05	0.000302	CcSEcCtD
Disopyramide—Confusional state—Epirubicin—breast cancer	4.1e-05	0.000301	CcSEcCtD
Disopyramide—Oedema—Epirubicin—breast cancer	4.07e-05	0.000298	CcSEcCtD
Disopyramide—Hypotension—Methotrexate—breast cancer	4.06e-05	0.000298	CcSEcCtD
Disopyramide—Loss of consciousness—Doxorubicin—breast cancer	4.05e-05	0.000297	CcSEcCtD
Disopyramide—Shock—Epirubicin—breast cancer	4e-05	0.000293	CcSEcCtD
Disopyramide—Diarrhoea—Capecitabine—breast cancer	4e-05	0.000293	CcSEcCtD
Disopyramide—Dizziness—Docetaxel—breast cancer	3.99e-05	0.000292	CcSEcCtD
Disopyramide—Thrombocytopenia—Epirubicin—breast cancer	3.98e-05	0.000292	CcSEcCtD
Disopyramide—Skin disorder—Epirubicin—breast cancer	3.95e-05	0.00029	CcSEcCtD
Disopyramide—Hyperhidrosis—Epirubicin—breast cancer	3.93e-05	0.000288	CcSEcCtD
Disopyramide—Insomnia—Methotrexate—breast cancer	3.93e-05	0.000288	CcSEcCtD
Disopyramide—Chest pain—Doxorubicin—breast cancer	3.93e-05	0.000288	CcSEcCtD
Disopyramide—Paraesthesia—Methotrexate—breast cancer	3.9e-05	0.000286	CcSEcCtD
Disopyramide—Discomfort—Doxorubicin—breast cancer	3.88e-05	0.000284	CcSEcCtD
Disopyramide—Anorexia—Epirubicin—breast cancer	3.88e-05	0.000284	CcSEcCtD
Disopyramide—Dyspnoea—Methotrexate—breast cancer	3.88e-05	0.000284	CcSEcCtD
Disopyramide—Somnolence—Methotrexate—breast cancer	3.86e-05	0.000283	CcSEcCtD
Disopyramide—Dizziness—Capecitabine—breast cancer	3.86e-05	0.000283	CcSEcCtD
Disopyramide—Dry mouth—Doxorubicin—breast cancer	3.84e-05	0.000281	CcSEcCtD
Disopyramide—Vomiting—Docetaxel—breast cancer	3.83e-05	0.000281	CcSEcCtD
Disopyramide—Dyspepsia—Methotrexate—breast cancer	3.83e-05	0.00028	CcSEcCtD
Disopyramide—Rash—Docetaxel—breast cancer	3.8e-05	0.000279	CcSEcCtD
Disopyramide—Hypotension—Epirubicin—breast cancer	3.8e-05	0.000279	CcSEcCtD
Disopyramide—Dermatitis—Docetaxel—breast cancer	3.8e-05	0.000278	CcSEcCtD
Disopyramide—Confusional state—Doxorubicin—breast cancer	3.8e-05	0.000278	CcSEcCtD
Disopyramide—Decreased appetite—Methotrexate—breast cancer	3.78e-05	0.000277	CcSEcCtD
Disopyramide—Headache—Docetaxel—breast cancer	3.78e-05	0.000277	CcSEcCtD
Disopyramide—Oedema—Doxorubicin—breast cancer	3.76e-05	0.000276	CcSEcCtD
Disopyramide—Fatigue—Methotrexate—breast cancer	3.75e-05	0.000275	CcSEcCtD
Disopyramide—Pain—Methotrexate—breast cancer	3.72e-05	0.000272	CcSEcCtD
Disopyramide—Vomiting—Capecitabine—breast cancer	3.71e-05	0.000272	CcSEcCtD
Disopyramide—Shock—Doxorubicin—breast cancer	3.7e-05	0.000271	CcSEcCtD
Disopyramide—Thrombocytopenia—Doxorubicin—breast cancer	3.69e-05	0.00027	CcSEcCtD
Disopyramide—Rash—Capecitabine—breast cancer	3.68e-05	0.00027	CcSEcCtD
Disopyramide—Insomnia—Epirubicin—breast cancer	3.68e-05	0.00027	CcSEcCtD
Disopyramide—Dermatitis—Capecitabine—breast cancer	3.68e-05	0.00027	CcSEcCtD
Disopyramide—Headache—Capecitabine—breast cancer	3.66e-05	0.000268	CcSEcCtD
Disopyramide—Skin disorder—Doxorubicin—breast cancer	3.66e-05	0.000268	CcSEcCtD
Disopyramide—Paraesthesia—Epirubicin—breast cancer	3.65e-05	0.000268	CcSEcCtD
Disopyramide—Hyperhidrosis—Doxorubicin—breast cancer	3.64e-05	0.000267	CcSEcCtD
Disopyramide—Dyspnoea—Epirubicin—breast cancer	3.63e-05	0.000266	CcSEcCtD
Disopyramide—Somnolence—Epirubicin—breast cancer	3.62e-05	0.000265	CcSEcCtD
Disopyramide—Anorexia—Doxorubicin—breast cancer	3.59e-05	0.000263	CcSEcCtD
Disopyramide—Nausea—Docetaxel—breast cancer	3.58e-05	0.000263	CcSEcCtD
Disopyramide—Feeling abnormal—Methotrexate—breast cancer	3.58e-05	0.000263	CcSEcCtD
Disopyramide—Dyspepsia—Epirubicin—breast cancer	3.58e-05	0.000262	CcSEcCtD
Disopyramide—Decreased appetite—Epirubicin—breast cancer	3.54e-05	0.000259	CcSEcCtD
Disopyramide—Hypotension—Doxorubicin—breast cancer	3.52e-05	0.000258	CcSEcCtD
Disopyramide—Fatigue—Epirubicin—breast cancer	3.51e-05	0.000257	CcSEcCtD
Disopyramide—Pain—Epirubicin—breast cancer	3.48e-05	0.000255	CcSEcCtD
Disopyramide—Constipation—Epirubicin—breast cancer	3.48e-05	0.000255	CcSEcCtD
Disopyramide—Nausea—Capecitabine—breast cancer	3.47e-05	0.000254	CcSEcCtD
Disopyramide—Urticaria—Methotrexate—breast cancer	3.45e-05	0.000253	CcSEcCtD
Disopyramide—Body temperature increased—Methotrexate—breast cancer	3.44e-05	0.000252	CcSEcCtD
Disopyramide—Insomnia—Doxorubicin—breast cancer	3.4e-05	0.000249	CcSEcCtD
Disopyramide—Paraesthesia—Doxorubicin—breast cancer	3.38e-05	0.000248	CcSEcCtD
Disopyramide—Dyspnoea—Doxorubicin—breast cancer	3.36e-05	0.000246	CcSEcCtD
Disopyramide—Feeling abnormal—Epirubicin—breast cancer	3.35e-05	0.000246	CcSEcCtD
Disopyramide—Somnolence—Doxorubicin—breast cancer	3.35e-05	0.000245	CcSEcCtD
Disopyramide—Dyspepsia—Doxorubicin—breast cancer	3.31e-05	0.000243	CcSEcCtD
Disopyramide—Decreased appetite—Doxorubicin—breast cancer	3.27e-05	0.00024	CcSEcCtD
Disopyramide—Fatigue—Doxorubicin—breast cancer	3.25e-05	0.000238	CcSEcCtD
Disopyramide—Urticaria—Epirubicin—breast cancer	3.23e-05	0.000237	CcSEcCtD
Disopyramide—Pain—Doxorubicin—breast cancer	3.22e-05	0.000236	CcSEcCtD
Disopyramide—Constipation—Doxorubicin—breast cancer	3.22e-05	0.000236	CcSEcCtD
Disopyramide—Body temperature increased—Epirubicin—breast cancer	3.22e-05	0.000236	CcSEcCtD
Disopyramide—Asthenia—Methotrexate—breast cancer	3.12e-05	0.000229	CcSEcCtD
Disopyramide—Feeling abnormal—Doxorubicin—breast cancer	3.1e-05	0.000227	CcSEcCtD
Disopyramide—Pruritus—Methotrexate—breast cancer	3.08e-05	0.000225	CcSEcCtD
Disopyramide—Urticaria—Doxorubicin—breast cancer	2.99e-05	0.000219	CcSEcCtD
Disopyramide—Body temperature increased—Doxorubicin—breast cancer	2.98e-05	0.000218	CcSEcCtD
Disopyramide—Diarrhoea—Methotrexate—breast cancer	2.97e-05	0.000218	CcSEcCtD
Disopyramide—Asthenia—Epirubicin—breast cancer	2.92e-05	0.000214	CcSEcCtD
Disopyramide—Pruritus—Epirubicin—breast cancer	2.88e-05	0.000211	CcSEcCtD
Disopyramide—Dizziness—Methotrexate—breast cancer	2.87e-05	0.000211	CcSEcCtD
Disopyramide—Diarrhoea—Epirubicin—breast cancer	2.78e-05	0.000204	CcSEcCtD
Disopyramide—Vomiting—Methotrexate—breast cancer	2.76e-05	0.000203	CcSEcCtD
Disopyramide—Rash—Methotrexate—breast cancer	2.74e-05	0.000201	CcSEcCtD
Disopyramide—Dermatitis—Methotrexate—breast cancer	2.74e-05	0.000201	CcSEcCtD
Disopyramide—Headache—Methotrexate—breast cancer	2.72e-05	0.0002	CcSEcCtD
Disopyramide—Asthenia—Doxorubicin—breast cancer	2.7e-05	0.000198	CcSEcCtD
Disopyramide—Dizziness—Epirubicin—breast cancer	2.69e-05	0.000197	CcSEcCtD
Disopyramide—Pruritus—Doxorubicin—breast cancer	2.66e-05	0.000195	CcSEcCtD
Disopyramide—Vomiting—Epirubicin—breast cancer	2.59e-05	0.00019	CcSEcCtD
Disopyramide—Nausea—Methotrexate—breast cancer	2.58e-05	0.000189	CcSEcCtD
Disopyramide—Diarrhoea—Doxorubicin—breast cancer	2.58e-05	0.000189	CcSEcCtD
Disopyramide—Rash—Epirubicin—breast cancer	2.56e-05	0.000188	CcSEcCtD
Disopyramide—Dermatitis—Epirubicin—breast cancer	2.56e-05	0.000188	CcSEcCtD
Disopyramide—Headache—Epirubicin—breast cancer	2.55e-05	0.000187	CcSEcCtD
Disopyramide—Dizziness—Doxorubicin—breast cancer	2.49e-05	0.000182	CcSEcCtD
Disopyramide—Nausea—Epirubicin—breast cancer	2.42e-05	0.000177	CcSEcCtD
Disopyramide—Vomiting—Doxorubicin—breast cancer	2.39e-05	0.000175	CcSEcCtD
Disopyramide—Rash—Doxorubicin—breast cancer	2.37e-05	0.000174	CcSEcCtD
Disopyramide—Dermatitis—Doxorubicin—breast cancer	2.37e-05	0.000174	CcSEcCtD
Disopyramide—Headache—Doxorubicin—breast cancer	2.36e-05	0.000173	CcSEcCtD
Disopyramide—Nausea—Doxorubicin—breast cancer	2.24e-05	0.000164	CcSEcCtD
Disopyramide—CHRM1—Signaling Pathways—TERT—breast cancer	3.57e-06	5.36e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TERT—breast cancer	3.56e-06	5.34e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL2—breast cancer	3.54e-06	5.31e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TERT—breast cancer	3.52e-06	5.29e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGFR1—breast cancer	3.47e-06	5.2e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—NOS3—breast cancer	3.46e-06	5.19e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGFR1—breast cancer	3.46e-06	5.19e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGFR1—breast cancer	3.42e-06	5.14e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HIF1A—breast cancer	3.41e-06	5.12e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CD—breast cancer	3.41e-06	5.12e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HIF1A—breast cancer	3.4e-06	5.11e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HIF1A—breast cancer	3.37e-06	5.06e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—ALB—breast cancer	3.37e-06	5.06e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—DPYD—breast cancer	3.35e-06	5.03e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MED12—breast cancer	3.35e-06	5.03e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—LEP—breast cancer	3.33e-06	5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—LEP—breast cancer	3.32e-06	4.99e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CAV1—breast cancer	3.3e-06	4.96e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALDOA—breast cancer	3.3e-06	4.95e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CAV1—breast cancer	3.29e-06	4.94e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—LEP—breast cancer	3.29e-06	4.94e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KDR—breast cancer	3.27e-06	4.9e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CAV1—breast cancer	3.26e-06	4.89e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KDR—breast cancer	3.26e-06	4.88e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KDR—breast cancer	3.22e-06	4.84e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—NOS3—breast cancer	3.22e-06	4.84e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOA3—breast cancer	3.2e-06	4.81e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CB—breast cancer	3.19e-06	4.79e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ESR1—breast cancer	3.18e-06	4.78e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SLC2A2—breast cancer	3.18e-06	4.77e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ESR1—breast cancer	3.17e-06	4.76e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTGS2—breast cancer	3.16e-06	4.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CD—breast cancer	3.15e-06	4.73e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FN1—breast cancer	3.14e-06	4.72e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ESR1—breast cancer	3.14e-06	4.71e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FN1—breast cancer	3.13e-06	4.7e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MTR—breast cancer	3.12e-06	4.68e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CPT1A—breast cancer	3.12e-06	4.68e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCG2—breast cancer	3.12e-06	4.68e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—ALB—breast cancer	3.11e-06	4.67e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NFKBIA—breast cancer	3.11e-06	4.66e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FN1—breast cancer	3.1e-06	4.66e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NFKBIA—breast cancer	3.1e-06	4.65e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NOTCH1—breast cancer	3.08e-06	4.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NOTCH1—breast cancer	3.07e-06	4.6e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NFKBIA—breast cancer	3.07e-06	4.6e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HPGDS—breast cancer	3.06e-06	4.59e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HBA1—breast cancer	3.04e-06	4.56e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NOTCH1—breast cancer	3.04e-06	4.56e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CG—breast cancer	3.01e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APC—breast cancer	3.01e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KIT—breast cancer	3.01e-06	4.51e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APC—breast cancer	3e-06	4.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CG—breast cancer	3e-06	4.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KIT—breast cancer	3e-06	4.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—NOS3—breast cancer	2.98e-06	4.47e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CB—breast cancer	2.97e-06	4.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGF—breast cancer	2.97e-06	4.46e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APC—breast cancer	2.97e-06	4.46e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KIT—breast cancer	2.97e-06	4.46e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CG—breast cancer	2.97e-06	4.46e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTT1—breast cancer	2.96e-06	4.45e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ACHE—breast cancer	2.96e-06	4.45e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGF—breast cancer	2.96e-06	4.45e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTGS2—breast cancer	2.95e-06	4.42e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGF—breast cancer	2.94e-06	4.4e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK3—breast cancer	2.88e-06	4.32e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK3—breast cancer	2.87e-06	4.31e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK3—breast cancer	2.84e-06	4.27e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—BRAF—breast cancer	2.83e-06	4.24e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—BRAF—breast cancer	2.82e-06	4.23e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP17A1—breast cancer	2.81e-06	4.21e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—BRAF—breast cancer	2.79e-06	4.19e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ENO1—breast cancer	2.78e-06	4.17e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTGS1—breast cancer	2.78e-06	4.17e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTEN—breast cancer	2.76e-06	4.14e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IGF1—breast cancer	2.75e-06	4.13e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT2—breast cancer	2.75e-06	4.13e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CB—breast cancer	2.75e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IGF1—breast cancer	2.75e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT2—breast cancer	2.74e-06	4.12e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—EGFR—breast cancer	2.74e-06	4.11e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—EGFR—breast cancer	2.73e-06	4.1e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP2D6—breast cancer	2.72e-06	4.09e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTGS2—breast cancer	2.72e-06	4.09e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IGF1—breast cancer	2.72e-06	4.08e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT2—breast cancer	2.72e-06	4.08e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—EGFR—breast cancer	2.71e-06	4.06e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOA2—breast cancer	2.67e-06	4.01e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CD—breast cancer	2.64e-06	3.97e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CD—breast cancer	2.64e-06	3.96e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	2.62e-06	3.93e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SERPINE1—breast cancer	2.62e-06	3.92e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	2.61e-06	3.92e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CD—breast cancer	2.61e-06	3.92e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SERPINE1—breast cancer	2.61e-06	3.91e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—FASN—breast cancer	2.59e-06	3.89e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—KRAS—breast cancer	2.59e-06	3.88e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	2.59e-06	3.88e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—BCHE—breast cancer	2.58e-06	3.87e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SERPINE1—breast cancer	2.58e-06	3.87e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—KRAS—breast cancer	2.58e-06	3.87e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTEN—breast cancer	2.57e-06	3.86e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—KRAS—breast cancer	2.56e-06	3.84e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SLC5A5—breast cancer	2.55e-06	3.83e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NOS3—breast cancer	2.5e-06	3.75e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NOS3—breast cancer	2.49e-06	3.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NOS3—breast cancer	2.47e-06	3.7e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NQO1—breast cancer	2.46e-06	3.7e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—SLC2A1—breast cancer	2.46e-06	3.7e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	2.38e-06	3.57e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTEN—breast cancer	2.37e-06	3.56e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	2.37e-06	3.56e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MDM2—breast cancer	2.37e-06	3.55e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP1B1—breast cancer	2.36e-06	3.54e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MDM2—breast cancer	2.36e-06	3.54e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—RAF1—breast cancer	2.36e-06	3.54e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—RAF1—breast cancer	2.35e-06	3.53e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—RELA—breast cancer	2.35e-06	3.53e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	2.35e-06	3.52e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—RELA—breast cancer	2.34e-06	3.52e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MDM2—breast cancer	2.34e-06	3.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ERBB2—breast cancer	2.34e-06	3.5e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—RAF1—breast cancer	2.33e-06	3.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ERBB2—breast cancer	2.33e-06	3.49e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—RELA—breast cancer	2.32e-06	3.48e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.32e-06	3.48e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ERBB2—breast cancer	2.31e-06	3.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CB—breast cancer	2.31e-06	3.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MTOR—breast cancer	2.31e-06	3.46e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MTOR—breast cancer	2.3e-06	3.45e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CB—breast cancer	2.3e-06	3.45e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CB—breast cancer	2.28e-06	3.41e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MTOR—breast cancer	2.28e-06	3.41e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOA1—breast cancer	2.25e-06	3.38e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP19A1—breast cancer	2.22e-06	3.33e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—STK11—breast cancer	2.22e-06	3.33e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CXCL8—breast cancer	2.22e-06	3.32e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CXCL8—breast cancer	2.21e-06	3.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—HRAS—breast cancer	2.2e-06	3.3e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—HRAS—breast cancer	2.19e-06	3.29e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CXCL8—breast cancer	2.19e-06	3.28e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—HRAS—breast cancer	2.17e-06	3.26e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1B—breast cancer	2.16e-06	3.25e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1B—breast cancer	2.16e-06	3.24e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—AKT1—breast cancer	2.14e-06	3.21e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1B—breast cancer	2.14e-06	3.2e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—AKT1—breast cancer	2.13e-06	3.2e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CASP3—breast cancer	2.12e-06	3.18e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL2—breast cancer	2.12e-06	3.18e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CASP3—breast cancer	2.11e-06	3.17e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—AKT1—breast cancer	2.11e-06	3.17e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL2—breast cancer	2.11e-06	3.17e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL6—breast cancer	2.11e-06	3.16e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL6—breast cancer	2.1e-06	3.15e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CASP3—breast cancer	2.09e-06	3.14e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL2—breast cancer	2.09e-06	3.14e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL6—breast cancer	2.08e-06	3.12e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—COMT—breast cancer	2.06e-06	3.1e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCND1—breast cancer	2.06e-06	3.1e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—JUN—breast cancer	2.06e-06	3.09e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCND1—breast cancer	2.06e-06	3.09e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTP1—breast cancer	2.05e-06	3.08e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—JUN—breast cancer	2.05e-06	3.08e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CTNNB1—breast cancer	2.04e-06	3.07e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCND1—breast cancer	2.04e-06	3.06e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CTNNB1—breast cancer	2.04e-06	3.06e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—JUN—breast cancer	2.03e-06	3.05e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HMOX1—breast cancer	2.03e-06	3.04e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ITPR1—breast cancer	2.02e-06	3.03e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CTNNB1—breast cancer	2.02e-06	3.03e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MMP9—breast cancer	2e-06	3.01e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MMP9—breast cancer	2e-06	3e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1A—breast cancer	2e-06	3e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PTEN—breast cancer	1.99e-06	2.99e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1A—breast cancer	1.99e-06	2.99e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PTEN—breast cancer	1.99e-06	2.98e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MMP9—breast cancer	1.98e-06	2.97e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1A—breast cancer	1.97e-06	2.96e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PTEN—breast cancer	1.97e-06	2.95e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK8—breast cancer	1.95e-06	2.92e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CA—breast cancer	1.95e-06	2.92e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCB1—breast cancer	1.94e-06	2.92e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—AKT1—breast cancer	1.94e-06	2.92e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK8—breast cancer	1.94e-06	2.91e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—AKT1—breast cancer	1.94e-06	2.91e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK8—breast cancer	1.92e-06	2.89e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—AKT1—breast cancer	1.92e-06	2.88e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—TYMS—breast cancer	1.91e-06	2.87e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.89e-06	2.83e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTM1—breast cancer	1.89e-06	2.83e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOR1—breast cancer	1.89e-06	2.83e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SRC—breast cancer	1.85e-06	2.77e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SRC—breast cancer	1.84e-06	2.76e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SRC—breast cancer	1.82e-06	2.74e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CA—breast cancer	1.81e-06	2.72e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GPX1—breast cancer	1.81e-06	2.71e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—VEGFA—breast cancer	1.8e-06	2.7e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—VEGFA—breast cancer	1.79e-06	2.69e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP1A1—breast cancer	1.79e-06	2.69e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—STAT3—breast cancer	1.78e-06	2.67e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—VEGFA—breast cancer	1.78e-06	2.66e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—STAT3—breast cancer	1.78e-06	2.66e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ERCC2—breast cancer	1.78e-06	2.66e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—STAT3—breast cancer	1.76e-06	2.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK3—breast cancer	1.7e-06	2.55e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK3—breast cancer	1.7e-06	2.55e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK3—breast cancer	1.68e-06	2.52e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CA—breast cancer	1.68e-06	2.51e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—MTHFR—breast cancer	1.67e-06	2.5e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MYC—breast cancer	1.66e-06	2.48e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TGFB1—breast cancer	1.65e-06	2.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MYC—breast cancer	1.65e-06	2.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TGFB1—breast cancer	1.65e-06	2.47e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MYC—breast cancer	1.63e-06	2.45e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TGFB1—breast cancer	1.63e-06	2.45e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGFR—breast cancer	1.62e-06	2.43e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGFR—breast cancer	1.61e-06	2.42e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGFR—breast cancer	1.6e-06	2.4e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AKT1—breast cancer	1.59e-06	2.38e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CAV1—breast cancer	1.54e-06	2.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KRAS—breast cancer	1.53e-06	2.29e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KRAS—breast cancer	1.52e-06	2.29e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KRAS—breast cancer	1.51e-06	2.27e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AKT1—breast cancer	1.48e-06	2.22e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.41e-06	2.11e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CG—breast cancer	1.4e-06	2.1e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CA—breast cancer	1.4e-06	2.1e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CA—breast cancer	1.39e-06	2.08e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AKT1—breast cancer	1.37e-06	2.05e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TP53—breast cancer	1.36e-06	2.04e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TP53—breast cancer	1.36e-06	2.03e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TP53—breast cancer	1.34e-06	2.01e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HRAS—breast cancer	1.3e-06	1.95e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HRAS—breast cancer	1.3e-06	1.94e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HRAS—breast cancer	1.28e-06	1.93e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6—breast cancer	1.24e-06	1.87e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6—breast cancer	1.24e-06	1.86e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CD—breast cancer	1.23e-06	1.85e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6—breast cancer	1.23e-06	1.84e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALB—breast cancer	1.22e-06	1.83e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NOS3—breast cancer	1.16e-06	1.75e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT1—breast cancer	1.15e-06	1.72e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT1—breast cancer	1.14e-06	1.72e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT1—breast cancer	1.13e-06	1.7e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CB—breast cancer	1.07e-06	1.61e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTGS2—breast cancer	1.06e-06	1.6e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTEN—breast cancer	9.28e-07	1.39e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CA—breast cancer	6.55e-07	9.83e-06	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKT1—breast cancer	5.35e-07	8.03e-06	CbGpPWpGaD
